Investors

Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity.

The company’s lead product candidate is beloranib, a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome, or PWS, craniopharyngioma-associated obesity, and severe obesity in the general population. Beloranib acts through potent inhibition of MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism.

Zafgen’s clinical portfolio also includes ZGN-839, a novel chemical class of MetAP2 inhibitor that the company is exploring as an oral treatment for nonalcoholic steatohepatitis, or NASH, and type 2 diabetes.



NASDAQ: ZFGN
$ 18.28 +0.26 (1.44%)
Day High: 18.28
Day Low:  17.98
Volume:    20,100
4:00 PM ET on
Oct 24, 2014

Delayed ~20 min., by eSignal.